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Abstract

Author Manuscript

Carboranyl-containing chlorins have emerged as promising dual sensitizers for use in both
photodynamic therapy (PDT) and boron neutron capture therapy (BNCT), by virtue of their
known tumor affinity, low cytotoxicity in dark conditions, and their strong absorptions in the red
region of the optical spectrum. Tetrakis(p-carboranylthio-tetrafluorophenyl)chlorin (TPFC) is a
new synthetic carboranyl-containing chlorin of high boron content (24% by weight). To evaluate
TPFC’s applicability as sensitizer for both PDT and BNCT, we performed an in vitro and in vivo
study using F98 rat glioma cells and F98 rat glioma-bearing brain tumor models. For the in vivo
BNCT study, we used boronophenylalanine (BPA), which is currently used in clinical BNCT
studies, via intravenous administration (i.v.) and/or used TPFC via convection-enhanced delivery
(CED), a method for local drug infusion directly into the brain. In the in vitro PDT study, the cell
surviving fraction following laser irradiation (9 J/cm2) was 0.035 whereas in the in vitro BNCT
study, the cell surviving fraction following neutron irradiation (thermal neutron = 1.73 × 1012
n/cm2) was 0.04. In the in vivo BNCT study, the median survival time following concomitant
administration of BPA (i.v.) and TPFC (CED) was 42 days (95% confidence interval; 37–43
days).

Author Manuscript
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INTRODUCTION
The prognosis of patients with malignant glioma, especially glioblastoma (GB), is poor. The
median survival of GB patients is less than 2 years after the initial diagnosis,1 with most
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recurrence occurring at the site of the original tumor. Therefore, more aggressive local
therapies are necessary to eradicate unresectable tumor cells that invade adjacent normal
brain tissue. Two adjuvant therapies with the potential to destroy these unresectable tumor
cells are photodynamic therapy (PDT)2,3 and boron neutron capture therapy (BNCT).4–7
PDT and BNCT are two binary modalities for malignant glioma treatment that rely on the
selective accumulation of a sensitizer within tumor tissue, followed by its activation upon
irradiation with either red light (in PDT) or low-energy neutrons (in BNCT). The
combination of PDT and BNCT using a single drug has several advantages, including
increased therapeutic effect due to the targeting of different cellular components and/or
mechanisms of tumor cell destruction.

Author Manuscript

Boronated porphyrins and their derivatives, in particular dihydroporphyrins or chlorins, are
promising dual PDT and BNCT sensitizers because they usually have low dark toxicity,
preferentially accumulate within tumor tissues and persist there for a considerable amount of
time.8–10 Moreover, their strong absorption of light wavelengths in the red region (~650
nm), which is characterized by the power of deeper penetration into most human tissues,11
makes them ideal candidates for in vivo phototherapeutic applications;12 on the other hand,
their high boron content enhances the efficiency of their interaction with thermal neutrons.
In 2008, a new carboranyl-containing chlorin, designated TPFC [tetrakis(p-carboranylthiotetrafluorophenyl)chlorin (TPFC)], containing four boron clusters (24% boron by weight),
was reported by our collaborator, Vicente and coworkers.13 This report showed that TPFC
was found to be non-toxic in the dark but showed extensive photosensitizing ability both in
vitro and in vivo despite its relatively low singlet oxygen quantum yield. In particular, TPFC
exhibited significant photosensitizing activity against highly pigmented melanotic
melanoma tumors in mice.

Author Manuscript

In our study, we evaluated the potential of TPFC as a dual sensitizer for both PDT and
BNCT using F98 rat glioma cells and F98 rat glioma-bearing brain tumor models. Although
several carboranyl-containing chlorins and their derivatives have been reported as dual
sensitizers for both PDT and BNCT,13–15 in most of these studies, in vivo investigations
were not conducted. Additionally, there were no reports of in vivo neutron irradiation study
using a carboranyl-containing chlorin administered by convection-enhanced delivery (CED),
a method for local drug infusion directly into the brain. This study is a first report of an in
vivo neutron irradiation study using a new carboranyl-containing chlorin (TPFC)
administered by CED.

MATERIALS AND METHODS
Author Manuscript

Boron Compounds
The TPFC was prepared as previously described.13 TPFC was dissolved in
dimethylsulfoxide (DMSO); the final DMSO concentrations never exceeded 1%.
Boronophenylalanine (BPA) (L-isomer), which is currently used in clinical BNCT studies,
was kindly supplied by the Stella Chemifa Corporation (Osaka, Japan) and was prepared as
a fructose complex.16
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F98 rat glioma cells produce infiltrating tumors in the brains of Fischer rats.17 The tumors
have been shown to be refractory to a number of treatment modalities, including radiation
therapy.18 Based on their in vivo histology, the F98 rat glioma cells have been characterized
as anaplastic or undifferentiated glioma.19 In the present study, F98 rat glioma cells were
kindly obtained from Dr. Barth (Department of Pathology, Ohio State University,
Columbus, Ohio). They were routinely cultivated in our laboratory in Dulbecco’s modified
Eagle medium supplemented with 10% fetal bovine serum and penicillin at 37°C in an
atmosphere of 5% CO2. All the materials for the culture medium were purchased from
Gibco Invitrogen (Grand Island, New York).
In Vitro Cellular Uptake Study

Author Manuscript
Author Manuscript

In Vitro PDT Study

Author Manuscript

In order to investigate the ability of TPFC for delivery of boron intracellularly, a cellular
uptake was conducted, in which the cells were exposed to 10 μg 10B/mL of TPFC or BPA
for 2.5, 6, 12, and 18 h. First, F98 rat glioma cells were seeded in 100 mm dishes (BD
Falcon™, Franklin Lakes, New Jersey), and the culture medium was exchanged for boron
compounds-containing (TPFC, BPA) culture medium just before confluence. In this study,
three 100 mm dishes for each designated time were used. After the completion of exposure,
boron compounds-containing culture medium was removed, and then the cells were washed
twice with 4°C phosphate-buffered saline (PBS) and detached with trypsin-ethylenediamine
tetraacetic acid solution. Medium was then added, and the cells countered and sedimented
(centrifugation: 214.2 G-force for 5 min). Cells were digested overnight with 1 N nitric acid
solution, and boron uptake was determined by inductively coupled plasma atomic emission
spectrometry (ICP-AES) using an iCAP6000 emission spectrometer (Hitachi HighTechnologies, Tokyo, Japan). PBS and trypsin-ethylenediamine tetraacetic acid solution
were purchased from Gibco Invitrogen, and the nitric acid solution was purchased from
Wako Pure Chemical Industries (Osaka, Japan).

In Vitro BNCT Study

F98 rat glioma cells were incubated in culture media without TPFC and with two different
doses of TPFC (2.5 and 5 μg 10B/mL) for 18 h in 150 cm2 flasks (TPPeq\0\ac(o,R),
Trasadingen, Switzerland). Following incubation, the cells were retrieved from the flasks,
seeded onto 60 mm dishes (BD Falcon™) with 104 cells each and irradiated with visible
light of 405 nm from a diode laser (Ball Semiconductor, Frisco, Texas). The cells were
evenly irradiated at powers of 0, 4.5, 9, and 18 J/cm2. Following laser irradiation, the cells
were seeded onto dishes, each with the same pre-determined number of cells, iteratively. All
cells were cultured for 7 days, then fixed in methanol and stained with tripan blue. Colonies
composed of more than 50 cells were counted and assessed by calculating the cell surviving
fraction (= colony-forming assays).

F98 rat glioma cells were transferred to the atomic reactor (KUR; Kyoto University
Research Reactor) and incubated with the only culture medium (= control) and 10
μg 10B/mL of TPFC or BPA-containing culture medium for 24 h. The cells were washed
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twice with PBS, detached with trypsin-ethylenediamine tetraacetic acid solution, and
centrifuged at 1500 rpm for 5 min. The culture medium was then added to 1 mL of the cell
suspension at a density of 1 × 106 cells/mL. Both types of cells were irradiated at KUR with
reactor thermal neutron beams of 9.63 × 108 (n/cm2·s) for 0, 10, 20, 30 min at 1.0 MW
reactor power. After neutron irradiation, colony-forming assays were performed as
described above.
Tumor Model

Author Manuscript

All male Fischer rats (200–250 mg, F344 NSlc; Japan SLC, Shizuoka, Japan) were
anesthetized with an intraperitoneal injection of Nembutal (50 mg/kg) and placed in a
stereotactic frame (Model 900; David Kopf Instruments, Tujunga, California). A midline
scalp incision was made and the bregma was identified. A 1 mm burr hole was made in the
right frontal region of the skull and a 22-gauge needle attached to a 25 μL syringe was
inserted into the caudate nucleus using the same stereotactic coordinates, with the needle tip
inserted 5 mm into the dura. An injection of 105 cells in 10 μL of serum free medium was
administered at a rate of 1 μL/min. After the infusion, the needle was left in place for 3 min
and the burr hole was then covered with bone wax and the scalp was sutured.
Convection-Enhanced Delivery

Author Manuscript

Convection-enhanced delivery, a method for local drug infusion directly into the brain,20
enables the distribution of any drugs homogeneously in the brain, keeping high
concentration at the target site without mechanical damage to the surrounding normal tissue.
CED depends on the bulk flow in the interstitial space produced by continuous slow infusion
into the brain under low positive pressure. Using this method, it is theoretically possible to
deliver drugs to regions where tumor cells invade microscopically with little accumulation
in the blood and other organs. Moreover, because it does not depend on the molecular
weight of the infused agent, this method allows the selection of many kinds of therapeutic
agents and/or carriers, such as liposomes, dendrimers, and nanotubes.21–25 Clinical trials of
targeted toxins with epidermal growth factor receptor, transferrin receptor, interleukin-13
receptor, and interleukin-4 receptor are reported in the leterature.22,26–29
In Vivo Biodistribution Study

Author Manuscript

For the biodistribution study, 10 days after tumor implantation, F98 rat glioma-bearing brain
tumor models were generally anesthetized, placed in a stereotactic frame as described above,
shaved and washed the skin over the rat’s scalp and back. The midline scalp incision and a
skull burr hole that were made when tumor models were made were re-opened and 5 mmlong cannula (ALZET Brain Infusion Kit 2; DURECT Corporation, Cupertino, California)
were inserted into the burr hole through the skull. A mid-scapular incision was made, by
spreading the subcutaneous tissue of the back to create a pocket for the infusion pump
(ALZET Osmotic Pumps 2001D; DURECT Corporation), to be inserted. This infusion
pump can administer compounds to animals over 24 h at a rate of 8 μL/h. After the insertion
of the infusion pump, a catheter leading to the brain cannula was attached to the
subcutaneous pocket. Finally, the midline scalp incision and the mid-scapular incision were
closed. The total amounts of TPFC administered via CED to each group of rats were 0.125,
0.25, and 0.5 mg per rat. We then assayed the 10B concentration of tumor, blood, normal
J Pharm Sci. Author manuscript; available in PMC 2015 April 30.
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brain, liver, spleen, kidney, heart, lung, skin, and muscle by ICP-AES. In this study, we
sampled normal tissues from both hemispheres and defined the normal tissue from the
tumor-bearing hemisphere as ipsilateral normal brain and the normal tissue from the other
hemisphere as contralateral normal brain. The normal brain of the ipsilateral side, at least a
couple of millimeters away from the tumor border, was sampled with approximately 1 g
for 10B content measurement. Similarly, the normal brain of the contralateral side,
symmetric relative to the ipsilateral sampling, was also sampled for the boron measurement.
Normal brain for the tumor-to-normal brain ratio (= T/N) determinations used normal brain
from the contralateral side.
In Vivo BNCT Study

Author Manuscript

For the therapy study, neutron irradiation was performed in an atomic reactor (KUR) 14
days after the implantation of 103 F98 rat glioma cells. The radiation field delivered to the
tissue during irradiation was composed mainly of thermal neutrons (<0.53 eV), gamma
photons, and heavy-charged particles (4He, 7Li, 1H, and 14C) from the 10B (n, alpha)7Li
capture reaction and the 14N(n, p)14C reaction with normal tissue nitrogen. The fast neutron
level (>10,000 eV) was very low and therefore ignored. The thermal neutron flux was
measured using 3 mm long gold wires placed on the surface of tumors. The average of the
thermal neutron flux was 6.08 × 108 (n/cm2/s) and the thermal neutron fluence became 2.19
× 1012 n/cm2 for 60 min irradiation. The equivalent dose was calculated using the equations
below.30
Equivalent dose (Gy-Eq) = DB × CBEB + DN × RBEN + Dγ × hours

Author Manuscript

Gy-Eq refers to a biologically equivalent X-ray dose that can give radiation effects totally to
the tissue, DB (boron dose) = 7.43 × 10−14 × boron concentration (μg10B/g) × Φ thermal
neutron fluence (Gy),DN (nitrogen dose) = 6.78 × 10−14 × nitrogen concentration (weight%)
×Φ thermal neutron fluence (Gy), Dγ (gamma-ray dose) = 0.83 Gy/h, RBEN is the RBE
(relative biological effectiveness) for DN and it equals 2.5, CBEB is the CBE (compound
biological effectiveness) for DB and, in the case of BPA, this value is 3.8 for the tumor
tissue and 1.35 for the normal brain.31–33 The nitrogen concentration (%) is estimated as 4%
and the RBE for Dγis 1.0.

Author Manuscript

Fischer rats were transported to the KUR, randomized at 14 days after implantation, and
divided into five experimental groups composed of 6–10 animals each. These groups
included untreated control and irradiated control animals without boron compounds. The
other three groups were composed of TPFC administered by CED, BPA administered by
intravenous injection, and a combination of TPFC and BPA group. Two and a half hours
after intravenous administration of BPA (250 mg/kg b.w.) and/or twelve hours after
termination of CED using TPFC (0.25 mg/rat), neutron irradiation was initiated. All
irradiated rats were anesthetized and put in a whole body stabilizer with their heads placed
out of the shield. The heads were irradiated at a reactor power of 1.0 MW for 1 h. After
neutron irradiation, the neutron irradiated animals and the neutron unirradiated animals
remained at KUR for observation. We checked the survival time of all rats.
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For the in vitro fluorescence microscopy study, F98 rat glioma cells were seeded in a twowell chamber mounted on glass slides with a cover (Thermo Fisher Scientific Inc.,
Rochester, NY), and the culture medium without TPFC was exchanged for TPFC-containing
culture medium just before confluence. The cells were exposed to 20 μg 10B/mL of TPFC
for 24 h. After exposure, the glass slides were washed with 4°C PBS and the two-well
chamber was removed. The nuclei specific Hoechest dye (Hoechst 33342; Lonza) was added
(10 μg/mL) and the glass slides mounted onto cover glasses using DPX Mountant for
histology (Fluka Biochemika 44581, Germany). The two-well chamber slides were observed
using an inverted fluorescence microscope system (BZ-8000; KEYENCE, Japan).

Author Manuscript

The in vivo fluorescence microscopy study was conducted twenty four hours after
termination of CED administration of TPFC to F98 rat glioma-bearing brain tumor model.
The rats were euthanized and strip preparations of the brains were made. Similar to the in
vitro fluorescence microscopy study, the strip preparations of brain were observed using an
inverted fluorescence microscope system (BZ-8000; KEYENCE).
Statistical Analysis
Values are presented as means ± SD. Statistical analysis was performed by the Kaplan Meier
method using JMP® Pro 10 (SAS Institute Inc., Cary, North Carolina).

RESULTS
In Vitro Cellular Uptake Study

Author Manuscript

The ICP-AES measured cellular boron concentrations obtained in the in vitro cellular
delivery study using TPFC were 40.8 ± 1.8, 47.4 ± 2.4, 65.4 ± 4.7, and 67.4 ± 1.9 ng10B/106
cells after 2.5, 6, 12, or 18 h of exposure, respectively. On the other hand, the values
obtained using BPA under the same conditions were 17.9 ± 1.4, 17.6 ± 1.6, 25.8 ± 1.3, and
36.7 ± 3.5 ng10B/106 cells after 2.5, 6, 12, or 18 h of exposure, respectively. These results
are shown in Figure 1.
In Vitro PDT Study

Author Manuscript

The cytotoxicity of TPFC determined by laser irradiation using a colony-forming assay
showed the surviving fraction of cells following exposure to TPFC (0, 2.5, and 5 μg 10B/mL
for 18 h) and laser irradiation to be: 0.238 ± 0.012, 0.007 ± 0.003, and unmeasurable value
(for TPFC = 2.5 μg 10B/mL for 18 h), and 0.043 ± 0.021, 0.004 ± 0.002, and unmeasurable
value (for TPFC = 5 μg 10B/mL for 18 h), using 4.5, 9, and 18 J/cm2 light dose, respectively.
The unmeasurable value means no colonies on dishes (<0.000) owing to the high
photocytotoxicity of TPFC under the experimental conditions. The surviving fractions for
the laser-only control (without TPFC) were 0.805 ± 0.135, 0.377 ± 0.046, and 0.315 ±
0.036, using 4.5, 9, and 18 J/cm2 light dose, respectively. These results are shown in Figure
2.

J Pharm Sci. Author manuscript; available in PMC 2015 April 30.

HIRAMATSU et al.

Page 7

In Vitro BNCT Study

Author Manuscript

The cytotoxicity of TPFC upon neutron irradiation was also evaluated with a colony forming
assay, performed on F98 rat glioma cells 7 days after irradiation with the reactor thermal
neutron beam. The results are shown in Figure 3. For the control groups exposed to the
neutron beam without boron compounds (BPA or TPFC), the surviving fraction decreased
only slightly, with increasing thermal neutron fluence, with determined values of 1, 0.98,
0.90, 0.71, and 0.64 for each neutron fluence of 0, 0.289, 0.578, 1.156, and 1.733 × 1012
n/cm2, respectively. On the other hand, the survival ratios of tumor cells treated with BPA or
TPFC decreased exponentially with the increase of neutron fluence. The cytotoxicity of
BNCT was especially significant in the TPFC group, with the determined cell surviving
fraction following thermal neutron for 30 minutes of 0.04.
In Vivo Biodistribution Study

Author Manuscript

The boron concentrations following CED of TPFC to the F98 rat glioma-bearing brain
tumor models at 24 h after termination of CED were also observed at different TPFC doses
(0.125, 0.25, and 0.5 mg TPFC/rat). The tumor boron concentrations showed the highest
concentrations at a dose of 0.25 mg TPFC/rat; the boron concentrations at a dose of 0.125,
0.25, and 0.5 mg TPFC/rat were 22.69 ± 1.79, 40.35 ± 11.78, and 29.56 ± 10.44 μg 10B/g,
respectively. Low concentrations were observed in the ipsilateral brain, the contralateral
brain, and the blood at the different TPFC doses: 0.21 ± 0.16, 2.01 ± 1.30, and 0.23 ± 0.35 in
the ipsilateral brain, 0.05 ± 0.03, 0.97 ± 0.40, and 0.14 ± 0.23 in the contralateral brain, and
0.82 ± 0.61, 0.46 ± 0.19, and 0.26 ± 0.01 in blood, respectively. Tumor/normal brain ratio
and tumor/blood ratio of boron at the different TPFC doses were 454, 42, and 211 for the
tumor/normal brain ratio and 28, 88, and 114 for the tumor/blood ratio, respectively.

Author Manuscript

Table 1 summarizes the biodistribution data (tumor, ipsilateral brain, contralateral brain, and
blood) for TPFC administered by CED. We first focused our efforts on the differences
corresponding to the time after termination of CED of TPFC up to 48 h. The boron
concentrations in F98 tumor nodules were 13.02 ± 0.78, 22.69 ± 1.79, and 9.75 ± 3.96
μg 10B/g at 0, 24, and 48 h after termination of CED of 0.125 mg/rat TPFC, respectively.
The boron concentrations in the ipsilateral brain, the contralateral brain, and the blood also
increased up to 24 h after termination of CED and decreased at 48 h after termination of
CED. The corresponding tumor/normal brain ratios for the three different times were 186,
454, and 975, respectively.

Author Manuscript

Table 2 summarizes the biodistribution data (liver, spleen, kidney, heart, lung, skin, and
muscle) obtained for TPFC administered by CED. The boron concentrations of all organs
showed very low dose.
In Vivo BNCT Study
Median survival times of control groups (untreated and irradiated groups), a TPFC
administered by CED group, a BPA administered by intravenous injection group and a
combination of TPFC and BPA group were 25 days [95% confidence interval (CI); 22–28
days], 26 days (95% CI; 26–33 days), 31 days (95% CI; 27–42 days), 36 days (95% CI; 30–
44 days), and 42 days (95% CI; 37–43 days), respectively. There is no over-lap in 95% CI
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between TPFC group and untreated group/ irradiated group. There is over-lap in 95% CI
between a TPFC group and a BPA group and a combination group. These results are shown
in Figure 4.
In Vitro/In Vivo Fluorescence Microscopy
In vitro fluorescence microscopy showed the intracellular chlorin fluorescence (Fig. 5a) and
the images observed from the co-localization experiment using the nucleus-specific Hochest
dye (Fig. 5b). These results show that TPFC was taken up into the cells and also localized in
the nuclei (Fig. 5c). In vivo fluorescence microscopy also showed fluorescence of tumor, as
shown in Figure 6.

DISCUSSION
Author Manuscript
Author Manuscript

PDT is a localized therapy that relies on the specific uptake of a photosensitizer in the tumor
relative to the surrounding normal tissue, followed by laser irradiation for activation of the
photosensitizer.12 The photoactivation of the sensitizer causes oxidative damage to a variety
of cellular targets via the release of singlet oxygen and other reactive oxygen species, with
subsequent tumor necrosis. To date, the clinical trials with PDT employed as an adjuvant
treatment for human gliomas have used the poorly defined heterogeneous porphyrin mixture
hematoporphyrin derivative (HpD) or its more enriched commercial preparation, Photofrin,2
which does not contain boron. These compounds have several draw backs. The most
significant are cutaneous photosensitivity lasting up to 8 weeks following treatment,34–36
they are a complex mixture of porphyrins which makes accurate study difficult,37 and the
wavelength of light absorption is not optimal for tissue penetration.38,39 Chlorin
photosensitizers show great promise for use in PDT.40–45 They have enhanced molar
extinction and electronic absorption peaks at longer wavelengths than HpD, allowing for
both increased tissue penetration and enhanced tumor photodestruction.40–42 Furthermore,
chlorins do not appear to cause severe cutaneous photosensitization after 24 h.41–43 In 2008,
a new carboranyl-containing chlorin (TPFC) was reported.13 As TPFC is a boron-containing
chlorin of high boron content (24% by weight), it is a promising dual sensitizer for the PDT
and BNCT of gliomas.

Author Manuscript

In a similar fashion to PDT, BNCT is a targeted chemo-radiation therapy that significantly
increases the therapeutic ratio relative to conventional radiotherapeutic modalities. In
BNCT, a 10B-labeled compound delivers therapeutic concentrations of 10B (~30 μg 10B/g
tumor) to the target tumor, with high tumor-to-blood and tumor-to-normal-tissue ratios and
low cytotoxicity.4,5 Subsequently the tumor is irradiated with epithermal neutrons that
become thermalized at a certain depth within the tissues. The short range (<10 μm) of the α
and 7Li high linear energy transfer (high-LET) particles released from the 10B(n,α)7Li
neutron capture reaction makes the tumor microdistribution of 10B critically important in
BNCT. As the high-LET particles are highly cytotoxic, their killing effect depends on the
site of generation. These characteristics contribute to the tumor selectivity and strong
tumoricidal activity of BNCT, with negligible damage to normal tissue. Therefore, if
sufficient quantities of boron can be selectively delivered to tumor tissues, BNCT could be
an ideal tumor-selective particle beam irradiation local therapy for malignant gliomas.
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Clinically, BPA and/or sodium borocaptate (BSH) are currently available for BNCT as
boron delivery agents. BPA is a boronated derivative of an essential amino acid (Lphenylalanine) that is actively taken up by tumor cells, presumably via the amino acid
transport mechanism. BSH, on the other hand, is believed to preferentially accumulate
within tumor tissue via a partially destroyed or leaky blood brain barrier. We have used both
of these boron delivery agents in combination in clinical BNCT studies, and have previously
reported on the survival benefit from BNCT for newly diagnosed GB patients6 as well as for
recurrent malignant glioma patients.7 However, the present results using BPA and/or BSH
are far from satisfactory, and the use of more effective boron delivery agents should provide
enhanced clinical outcomes for BNCT. The so-called third-generation of boron delivery
agents,5 including boronated porphyrin derivatives, carboranyl-containing chlorins,
molecular-targeted agents (e.g., to EGFR), and liposome-linked boron delivery agents could
potentially greatly increase the efficacy of BNCT. Among these boron delivery agents,
carboranyl-containing chlorin TPFC is particularly promising because of its high boron
content compared with other reported boron-containing chlorins, and also because TPFC has
shown high efficacy as photosensitizer for PDT.13

Author Manuscript

In this study, our results show the efficacy of TPFC in both the in vitro PDT study (Fig. 2)
and in the in vitro BNCT study (Fig. 3), TPFC was highly phototoxic and showed equal or
superior performance compared with BPA upon neutron irradiation (Fig. 3). However in
vivo TPFC did not show as high antitumor effect than BPA following neutron irradiation
(Fig. 4). Although there are no great differences between the TPFC, BPA, and the
combination of TPFC and BPA groups, the later combination of TPFC and BPA group
showed the tendency to extend the survival time. It is possible that if PDT was followed by
BNCT, greater survival times could have been observed. In the fluorescence microscopy
experiment, TPFC was shown to be taken up by F98 rat glioma cells in vitro and by F98 rat
glioma tumor in vivo (Figs. 5 and 6). However, the sites of localization of TPFC might be
different following different routes of administration. Our results suggest that TPFC has
promise as dual sensitizer for both PDT and BNCT of gliomas. Additionally, TPFC could
also be used intraoperatively for photodynamic diagnosis (PDD) and fluorescence-guided
resection of brain tumors.

Author Manuscript

Pre-operative administration of a carboranyl-containing chlorin has a number of advantages
in the clinical setting. As shown in Figure 6, carboranyl-containing chlorins could be useful
in PDD and in fluorescence-guided resection of brain tumors during surgery. Using
fluorescence-guided resection of such tumors during surgery, the resection rate can be
augmented, with expected further improvements in patient prognosis.46 In addition,
carboranyl-containing chlorins can be used with intra-operative PDT and post-operative
BNCT. Although the initial results with commonly used photosensitizers for PDT such as
Photofrin (or its unpurified form HpD) were encouraging, treatment failures did occur,
mainly due to the limited penetration of light of 630 nm wavelength (=Photofrin and HpD)
into the brain. Penetration of light of 630 nm, recorded by Muller and Wilson,47,48 for
tumor, brain infiltrated by tumor and normal brain is 2.9 ± 1.5, 2.4 ± 1.2, and 1.5 ± 0.4 mm,
respectively. However, TPFC has a large molar coefficient at 652 nm (ε ~ 30,000 in
DMSO),13 which is characterized by the power of deep penetration into most human tissues.
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Nevertheless PDT alone will probably not be sufficient for malignant glioma treatment. In
cases with deep lesions, PDT alone may be inadequate to achieve complete tumor treatment,
and it would be preferable in such cases to use BNCT as a supplementary treatment, using a
boron-containing photosensitizer such as TPFC. Fairchild et al.49 reported that thermal and
epithermal neutrons are transported to a depth of approximately 10 cm, and BNCT has been
shown to be adequate for the treatment of deep lesions. As boron-containing chlorins can be
effective for BNCT as boron delivery agents while retaining their photosensitizer ability, the
limited penetration of light can be overcome using a combination of BNCT and PDT for the
treatment of human gliomas.

CONCLUSIONS
Author Manuscript

The present study demonstrates that TPFC is a promising dual sensitizer for PDT and BNCT
of F98 rat gliomas. In in vitro studies, TPFC is shown to be extremely phototoxic and to
localize near the cell nuclei. In addition, both in vitro and in vivo, TPFC was efficient at
treating F98 rat gliomas, comparable to known BPA. Interestingly, an in vivo study using a
combination of TPFC and BPA showed the greatest rat survival times (mean value of 42
days), compared to TPFC alone (mean of 31 days) and BPA alone (mean of 36 days).
Additionally, TPFC could be used in PDD and fluorescence-guided resection, as it is highly
fluorescent.
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BNCT

boron neutron capture therapy

BPA

boronophenylalanine

BSH

sodium borocaptate

CBE

compound biological effectiveness

CED

convection-enhanced delivery

CI

confidence interval

DMSO

dimethylsulfoxide

GB

glioblastoma

HpD

hematoporphyrin derivative

KUR

Kyoto University Research Reactor

LET

linear energy transfer
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phosphate-buffered saline
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PDD

photodynamic diagnosis

PDT

photodynamic therapy

RBE

relative biological effectiveness

TPFC

tetrakis(p-carboranylthio-tetrafluorophenyl)chlorin
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Figure 1.

TPFC’s cellular uptake of boron (ng10B/106 cells) was about twice as high as BPA’s cellular
uptake of boron on each time.

Author Manuscript
Author Manuscript
J Pharm Sci. Author manuscript; available in PMC 2015 April 30.

HIRAMATSU et al.

Page 15

Author Manuscript
Author Manuscript
Figure 2.
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Colony-forming assay using F98 rat glioma cells exposed to 0 (control), 2.5, and 5
μg 10B/mL of TPFC and irradiated with light doses of 0, 4.5, 9, and 18 J/cm2, respectively.
The most efficient PDT-induced tumoricidal effect was achieved when the cells were
irradiated with 9 J/cm2, 18 h after exposure to 5 μg 10B/mL of TPFC (less than 0.05).

Author Manuscript
J Pharm Sci. Author manuscript; available in PMC 2015 April 30.

HIRAMATSU et al.

Page 16

Author Manuscript
Author Manuscript
Author Manuscript

Figure 3.

F98 rat glioma cells were exposed to culture medium without boron compound (= control),
with 10 μg 10B/mL of BPA or TPFC for 24 h. Then they were irradiated with thermal
neutron, respectively. BPA’s cell surviving fraction following thermal neutron for 30 min
was 0.12. On the other hand, TPFC’s cell surviving fraction following thermal neutron for
30 min was 0.04.
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Median survival times of untreated group, irradiated group, TPFC group, BPA group, and
TPFC + BPA group were 25 days (95% CI; 22–28 days), 26 days (95% CI; 26–30 days), 31
days (95% CI; 27–42 days), 36 days (95% CI; 30–44 days), and 42 days (95% CI; 37–43
days), respectively (yellow, green, blue, brown, and red line indicated untreated, irradiated,
TPFC, BPA, and TPFC and BPA group, respectively.). It was significantly between TPFC
group and TPFC + BPA group (p value = 0.007 by Log-rank test and 0.004 by Wilcoxon
test). However, it was no significantly between BPA group and TPFC + BPA group (p value
= 0.350 by Log-rank test and 0.133 by Wilcoxon test). And it was no significantly between
TPFC group and BPA group (p value = 0.110 by Log-rank test and 0.063 by Wilcoxon test).
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Figure 5.

(a) Fluorescence of chlorin (TPFC), (b) nuclear fluorescence by the Hoechst dye (excitation
wavelength was 340–380 nm), (c) merged image (magnification of all images: ×400), and
(d) bright field image.
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Figure 6.

In vivo fluorescence microscopy also showed fluorescence of tumor. Red fluorescence
indicated the tumor and green fluorescence indicated the normal brain.
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T/B is tumor/blood.

T/N is tumor/normal brain (ipsilateral brain).
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